Katoh Shigeru, Goi Takanori, Naruse Takayuki, Ueda Yuki, Kurebayashi Hidetaka, Nakazawa Toshiyuki, Kimura Youhei, Hirono Yasuo, Yamaguchi Akio
First Department of Surgery, University of Fukui, Fukui, Japan.
First Department of Surgery, University of Fukui, Fukui, Japan
Anticancer Res. 2015 Jan;35(1):239-44.
BACKGROUND/AIM: The expression of the CD44 variant exon 9 (CD44v9) was investigated in order to elucidate its significance for cancer stem cells in circulating human colorectal cancer cells (CTCs).
After peripheral blood was drawn from patients with colorectal cancer, CTCs were collected. Using the reverse transcription-polymerase chain reaction method, we examined the relationship between expression of CD44v9 mRNA and prognosis.
In 60 out of 150 patients with colorectal cancer, expression of CD44v9 mRNA was positive in CTCs. In patients with stage III disease, the 5-year survival rate was 89% for patients with negative CD44v9 expression, whereas it was 52.4% in patients with positive expression (p<0.05). In patients with stage IV unresectable cancer, the 2-year survival rate was 70.1% in cases with CD44v9-negative expression and 33.3% in cases of positive expression (p<0.05).
CD44v9 mRNA in the CTCs of colorectal cancer is useful as a factor predicting recurrence, prognosis, and treatment efficacy.
背景/目的：研究CD44变异外显子9（CD44v9）的表达，以阐明其在循环人结肠癌细胞（CTC）中对癌症干细胞的意义。
从结直肠癌患者中采集外周血后收集CTC。采用逆转录-聚合酶链反应方法，我们检测了CD44v9 mRNA表达与预后之间的关系。
150例结直肠癌患者中，60例患者的CTC中CD44v9 mRNA表达呈阳性。在III期疾病患者中，CD44v9表达阴性的患者5年生存率为89%，而表达阳性的患者为52.4%（p<0.05）。在IV期不可切除癌症患者中，CD44v9阴性表达患者的2年生存率为70.1%，阳性表达患者为33.3%（p<0.05）。
结直肠癌CTC中的CD44v9 mRNA可作为预测复发、预后和治疗效果的一个因素。
Zotero 插件